Brief: Scancell And Neuphoria Therapeutics Announce Merger Agreement
BRIEF-Scancell And Neuphoria Therapeutics Announce Merger Agreement July 23 (Reuters) - Scancell Holdings PLC SCLP.L:
SCANCELL HOLDINGS - MERGER AND FINANCING
SCANCELL - CO AND NEUPHORIA THERAPEUTICS ANNOUNCE MERGER AGREEMENT
SCANCELL - ALL-SHARE DEAL TO CREATE COMBINED COMPANY OPERATING AS SCANCELL
SCANCELL - COMBINED COMPANY TO BE LISTED ON NASDAQ AND AIM
SCANCELL - SHAREHOLDERS TO OWN 85.5%, NEUPHORIA SHAREHOLDERS 14.5% OF COMBINED COMPANY
SCANCELL - EXPECTS TO SECURE UP TO $89 MILLION IN FINANCING
SCANCELL - FINANCING TO FUND GLOBAL PHASE 3 TRIAL FOR ISCIB1+ IN ADVANCED MELANOMA
SCANCELL - ENTERS NON-BINDING TERM SHEET WITH BLACKROCK FOR DEBT FINANCING UP TO $25 MILLION
SCANCELL - MERGER EXPECTED TO PROVIDE MINIMUM $10 MILLION ADDITIONAL CASH FROM NEUPHORIA
SCANCELL HOLDINGS PLC: TRANSACTION UNANIMOUSLY APPROVED BY BOARD OF DIRECTORS OF EACH COMPANY
Source text: ID:nRSW5640Na
Further company coverage: SCLP.L